{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma%2C+Relapsed&page=2", "query": { "condition": "Multiple Myeloma, Relapsed", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma%2C+Relapsed&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T00:57:11.428Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05391750", "title": "Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-10-19", "completion_date": "2028-02-12", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05391750" }, { "nct_id": "NCT00639002", "title": "A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib 25 mg", "type": "DRUG" }, { "name": "Dexamethasone 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 3, "location_summary": "Highland, California • Boynton Beach, Florida • New York, New York", "locations": [ { "city": "Highland", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00639002" }, { "nct_id": "NCT02757326", "title": "ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Opaganib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedHill Biopharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-12-13", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02757326" }, { "nct_id": "NCT02188368", "title": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "POM", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "CFZ", "type": "DRUG" }, { "name": "BTZ", "type": "DRUG" }, { "name": "CLA", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-07-07", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 12, "location_summary": "Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188368" }, { "nct_id": "NCT05918250", "title": "mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "mRNA-2736", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-08-15", "completion_date": "2026-05-27", "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Miami, Florida • St Louis, Missouri + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05918250" }, { "nct_id": "NCT02718833", "title": "A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-06-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718833" }, { "nct_id": "NCT05346809", "title": "Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma", "Non-Hodgkin Lymphoma", "Relapsed Hodgkin's Disease, Adult" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Standard Procedures", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Divaya Bhutani", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-03-31", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 2, "location_summary": "Detroit, Michigan • New York, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346809" }, { "nct_id": "NCT07075185", "title": "A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma in Relapse", "Myeloma Multiple", "Multiple Myeloma Progression", "Neoplasms by Histologic Type", "Neoplasm", "Hemostatic Disorders", "Vascular Disorder", "Paraproteinemias", "Blood Protein Disorders", "Hematologic Disease and Disorders", "Lymphoproliferative Disorders", "Immunoproliferative Disorders", "Immune System Disease", "Gene Therapy" ], "interventions": [ { "name": "KLN-1010", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kelonia Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-07-16", "completion_date": "2042-05", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 7, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07075185" }, { "nct_id": "NCT01023308", "title": "Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 767, "start_date": "2009-12-21", "completion_date": "2015-07-30", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Anaheim, California • Concord, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023308" }, { "nct_id": "NCT00806065", "title": "Study of ENMD-2076 in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "ENMD-2076", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CASI pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-12", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-07-24T00:57:11.428Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806065" } ] }